HYPD EBITDA | HYPERION DEFI, INC.

HYPERION DEFI, INC. (HYPD) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income $31.01M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income $8.73M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income $4.43M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$8.35M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2016-12-31 to 2024-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	$31.01M	(m)	$357.69K	(m)	(m)	-$2.90M*	(m)	$58.49K	$3.92M	(m)
2026-03-31	Reported	(m)	$8.73M	(m)	$244.27K	(m)	(m)	-$4.20M	(m)	$286.76K	$4.49M	(m)
2025-09-30	Reported	(m)	$4.43M	(m)	$302.51K	(m)	(m)	-$2.82M*	(m)	$373.86K	$2.59M	(m)
2025-06-30	Reported	(m)	-$8.35M	(m)	$0.00*	(m)	(m)	-$3.45M*	(m)	$674.58K	$7.68M	(m)
2025-03-31	Reported	(m)	-$3.03M	(m)	$14.72K	(m)	(m)	-$4.44M	(m)	$673.04K	$2.37M	(m)
2024-12-31	Reported	-$19.15M	(m)	(m)	(m)	-68178.14%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$7.04M*	-$7.33M	$287.48K*	$1.63K	-433504.37%*	$1.62K*	-$5.94M*	(m)	$3.47M	$3.73M	(m)
2024-06-30	Reported	-$11.39M*	-$11.69M	$295.40K*	$22.63K	-50355.57%*	$45.75K*	-$8.17M*	(m)	$4.60M	$3.76M	(m)
2024-03-31	Reported	-$10.02M	(m)	(m)	(m)	-200662.85%	$114.11K	-$9.89M	(m)	$4.43M	(m)	(m)
2023-12-31	Reported	-$7.19M	(m)	(m)	(m)	-277675.94%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$6.20M*	-$6.52M	$318.42K*	$1.20K	-517676.88%*	$580.16K*	-$5.84M*	(m)	$3.58M	$2.93M	(m)
2023-06-30	Reported	-$5.84M*	-$5.96M	$124.15K*	(m)	(m)	$1.20M*	-$4.71M*	(m)	$2.81M	(m)	(m)
2023-03-31	Reported	-$5.4M	(m)	(m)	(m)	(m)	$920.87K	-$6.96M	(m)	$2.52M	(m)	(m)
2022-12-31	Reported	-$5.29M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$7.15M*	-$7.23M	$83.00K*	$0.00	(m)	$228.03K*	-$6.82M*	(m)	$3.88M	(m)	(m)
2022-06-30	Reported	-$7.05M*	-$7.12M	$70.47K*	$0.00	(m)	$106.78K*	-$4.70M*	(m)	$3.59M	(m)	(m)
2022-03-31	Reported	-$7.11M	(m)	(m)	(m)	(m)	$174.57K	-$8.18M	(m)	$3.71M	(m)	(m)
2021-12-31	Reported	$3.13M	(m)	(m)	(m)	31.27%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$5.85M*	-$5.93M	$73.00K*	$0.00	(m)	$517.32K*	$1.70M*	(m)	$3.55M	(m)	(m)
2021-06-30	Reported	-$4.74M*	-$4.78M	$41.96K*	$2.00M	-237.01%*	$303.42K*	-$5.33M*	(m)	$3.68M	(m)	(m)
2021-03-31	Reported	-$5.33M	(m)	(m)	(m)	-266.67%	$344.32K	-$4.57M	(m)	$4.32M	(m)	(m)
2020-12-31	Reported	-$4.18M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$5.07M*	-$5.09M	$22.29K*	(m)	(m)	$69.80K*	-$1.94M*	(m)	$3.36M	(m)	(m)
2020-06-30	Reported	-$5.00M*	-$5.02M	$21.11K*	$0.00	(m)	$38.31K*	-$4.00M*	(m)	$2.92M	(m)	(m)
2020-03-31	Reported	-$5.44M	(m)	(m)	(m)	(m)	$93.93K	-$5.92M	(m)	$3.63M	(m)	(m)
2019-12-31	Reported	-$5.28M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$4.69M*	-$4.69M	$3.39K*	(m)	(m)	$43.48K*	-$3.86M*	(m)	$3.20M	(m)	(m)
2019-06-30	Reported	-$5.37M*	-$5.38M	$2.55K*	(m)	(m)	$0.00*	-$5.14M*	(m)	$3.57M	(m)	(m)
2019-03-31	Reported	-$5.95M	(m)	(m)	(m)	(m)	$0.00	-$5.90M	(m)	$4.01M	(m)	(m)
2018-12-31	Reported	-$6.18M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$4.32M*	-$4.32M	$5.33K*	(m)	(m)	$0.00*	-$3.57M*	(m)	$2.49M	(m)	(m)
2018-06-30	Reported	-$3.31M*	-$3.32M	$6.16K*	(m)	(m)	$0.00*	-$3.04M*	(m)	$2.41M	(m)	(m)
2018-03-31	Reported	-$3.43M	(m)	(m)	(m)	(m)	$0.00	-$2.39M	(m)	$2.09M	(m)	(m)
2017-12-31	Reported	-$2.15M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$886.09K*	-$885.28K	-$812.00*	(m)	(m)	-$6.97K*	-$824.71K*	(m)	$570.42K	(m)	(m)
2017-06-30	Reported	-$970.72K*	-$976.88K	$6.16K*	(m)	(m)	-$2.01K*	-$1.04M*	(m)	$751.93K	(m)	(m)
2017-03-31	Reported	-$1.1M	(m)	(m)	(m)	(m)	$12.24K	-$868.88K	(m)	$910.84K	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$46.72M	(m)	$813.46K	(m)	(m)	-$14.77M	(m)	$1.91M	$17.18M	-$30.94K
2024-12-31	Reported	-$47.61M	(m)	(m)	(m)	-83036.44%	$161.48K	-$30.12M	(m)	$14.46M	$14.33M	(m)
2023-12-31	Reported	-$24.62M	(m)	(m)	(m)	-650204.33%	$2.85M	-$23.84M	(m)	$12.98M	$12.42M	(m)
2022-12-31	Reported	-$26.6M	(m)	(m)	(m)	(m)	$540.36K	-$25.11M	(m)	$13.38M	(m)	(m)
2021-12-31	Reported	-$12.8M	(m)	(m)	(m)	-91.42%	$1.23M	-$20.87M	(m)	$14.85M	(m)	(m)
2020-12-31	Reported	-$19.69M	(m)	(m)	(m)	-984.69%	$261.26K	-$6.38M	(m)	$13.36M	(m)	(m)
2019-12-31	Reported	-$21.29M	(m)	(m)	(m)	(m)	$166.64K	-$18.92M	(m)	$14.10M	(m)	$0.00
2018-12-31	Reported	-$17.24M	(m)	(m)	(m)	(m)	$27.91K	-$13.11M	(m)	$11.12M	(m)	$0.00
2017-12-31	Reported	-$5.11M	(m)	(m)	(m)	(m)	$10.23K	-$4.73M	(m)	$3.82M	(m)	$0.00
2016-12-31	Reported	-$3.52M	(m)	(m)	(m)	(m)	$43.12K	-$3.20M	(m)	$2.97M	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Rein Therapeutics, Inc. (RNTX)	United States	$0.063B	-1.76
XBiotech Inc. (XBIT)	United States	$0.066B	-1.56
Skye Bioscience, Inc. (SKYE)	United States	$0.061B	-0.48
CalciMedica, Inc. (CALC)	United States	$0.061B	-1.42
TALPHERA, INC. (TLPH)	United States	$0.060B
Connect Biopharma Holdings Ltd (CNTB)		$0.069B	-2.17
Yarrow Bioscience, Inc. (YARW)	United States	$0.070B
Boundless Bio, Inc. (BOLD)	United States	$0.059B	-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)	United States	$0.058B
PLIANT THERAPEUTICS, INC. (PLRX)	United States	$0.071B	-0.76